Karl Naegler 

  •                                 
    Extbase Variable Dump
    'distribution:BiomSpeaker.html' (29 chars)
    
                            
  •                                     
    Extbase Variable Dump
    'fileadmin/Webdata/Uploads/Veranstaltungen/2025/BayOConnect_2025/Speaker/Naeg
     ler_300x300.jpg    ' (91 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Karl Naegler' (12 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Partner, Sofinnova Partners' (27 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Karl Naegler is a Partner in the Sofinnova Capital Strategy. He joined us in
      September 2024, bringing a strong track record of 20 years of investment ex
     perience. Before joining Sofinnova, he was a Managing Partner at Wellington 
     Partners Life Sciences and before that, a Partner at Gimv. In those roles, h
     e was instrumental in the success of several high-profile startups, from com
     pany formation to exit. These include Seamless Therapeutics, launched with a
      top syndicate of investors; Breath Therapeutics, a co-investment with Sofin
     nova, acquired by Zambon; Covagen, acquired by Johnson & Johnson, and Proson
     ix, acquired by Circassia Pharmaceuticals.<br> "Sofinnova is a world-class f
     irm that truly leads life sciences venture capital in Europe. The opportunit
     y to be part of an investment platform spanning multiple sectors, stages and
      geographies, with such a high-caliber team, was an opportunity I could not 
     pass up. I look forward to bringing my experience to bear as we build and su
     pport the most innovative companies in life sciences across Europe."<br> His
      career also includes key roles at Ventech and Atlas Venture. Karl earned hi
     s PhD in Molecular Neurobiology from the Max-Delbrück-Center for Molecular M
     edicine in Berlin followed by a position as Scientific Fellow at CNRS for Ne
     urochemistry in Strasbourg.    ' (1319 chars)